What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

By Blood Cancer Talks - Last Updated: April 18, 2024

In this episode of “Blood Cancer Talks,” Raajit Rampal, MD, PhD, a Leukemia Specialist at the Memorial Sloan Kettering Cancer Center, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; to discuss the diagnosis and management of essential thrombocythemia.

Specifically, they discuss the revised International Prognostic Score in Essential Thrombocythemia (IPSET), in which risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status.

Next, they give a rundown of essential thrombocythemia treatment options, such as anagrelide, ruxolitinib, and twice-daily aspirin. The podcast dives into the MAJIC-ET trial, a randomized, phase II study that observed no differences in hematological responses with ruxolitinib compared with best available therapy.

This podcast originally appeared on Blood Cancer Talks. 

Editorial Board